Evidence mapPaperPMID 41904104Full record

ReviewTrends in endocrinology and metabolism: TEM2026

Improving incretin-mediated body weight loss via energy expenditure.

Andrew J Elmendorf, Jonathan D Douros, Patrick J Knerr, Jonathan N Flak

Abstract readReview
In one paragraph

Review in Trends in endocrinology and metabolism: TEM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andrew J ElmendorfDepartment of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.
Jonathan D DourosIndiana Biosciences Research Institute, Indianapolis, IN, USA.
Patrick J KnerrIndiana Biosciences Research Institute, Indianapolis, IN, USA.
Jonathan N FlakDepartment of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: jflak@iu.edu.

Funding

RESEARCH TRAINING PROGRAM IN DIABETES AND OBESITYT32DK064466 · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · 2003 to 2025
$779k
Defining the neurocircuit activated by the VMH to control energy expenditure.R01DK136897 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$509k
NIDDK NIH HHS R01 DK136897NIDDK NIH HHS T32 DK064466
6 · The paper itself

Abstract

Incretin-based therapies have transformed obesity and type 2 diabetes treatment. While current therapeutics safely reduce food intake and lower body weight, a compensatory drop-in basal metabolic rate represents a barrier to sustainable weight loss. Current efforts aim to incorporate energy expenditure (EE) stimulation with the anorectic actions currently available in the clinic. Glucagon receptor agonism, for instance, has demonstrated the benefit of a multipronged increase in EE; however, compensatory challenges persist. We detail peripheral mechanisms that can increase EE independent of activity and the key central mechanisms controlling them. Understanding the complex interplay between these mechanisms and their central modulation is critical for a coordinated engagement of EE pathways to complement and improve current weight loss treatments.

Indexed as

Energy MetabolismIncretinsObesityWeight LossAnimalsDiabetes Mellitus, Type 2HumansIncretinscentral nervous systemenergy expenditureglucagonincretinsobesitytype 2 diabetes

Identifiers

PMID41904104
PMCPMC13098988

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.